Abstract. Toll-like receptors (TLRs) play important roles in host resistance to infections, but also act as mediators of pathologies in autoimmunity, septic shock, metabolic disease and cancer. TLRs are expressed in sentinel cells of the immune system (most notably dendritic cells and macrophages) and are key sensors of bacteria, viruses, fungi and protozoa (O'Neill 2006) . TLRs also recognize endogenous ligands present in tissues and cells in the absence of infection Nizet 2006; Kim et al. 2009 ). In this review, the TLRs are characterized at the cellular level with emphasis on TLR-mediated signaling pathways along with their negative regulation, including specificity of the response(s) at the promoter level.
Introduction
Toll-like receptors (TLRs) are type I transmembrane proteins, whose name was coined based on similarity to Toll, a developmental control gene identified in the fruit fly Drosophila melanogaster in 1985 (Hansson and Edfeldt 2005) . In 1996, it was found that Toll also activates the synthesis of anti-microbial peptides, thus protecting the fly from infections (Lemaitre et al. 1996) . TLR4 was the first mammalian TLR to be identified by its role in lipopolysaccharide (LPS)-responsiveness and based on its homology to Toll. Currently, the TLR family has 11 members (Ulevitch 1999; Underhill et al. 1999 ).
Whereas TLR1, TLR2, TLR4 and TLR6 mainly recognize bacterial and fungal cell wall components, such as LPS and lipopeptides and TLR5 binds flagellin (a monomeric constituent of bacterial flagella) (Hayashi et al. 2001 ), TLR3, TLR7, TLR8 and TLR9 recognize nucleic acid structures, which serve as molecular signatures for viral infections (Dunne and O'Neill 2005) . Consistent with their role in microbial recognition, TLR1, 2, 4, 5 and 6 are expressed on the surface of myeloid lineage cells, whereas TLR3, 7, 8 and 9 are localized in endosomal/lysosomal membranes, a location that is more suitable for recognition of viruses (Gewirtz et al. 2001; Dunne and O'Neill 2005) .
The cytoplasmic regions of TLRs share a protein motif known as the Toll/interleukin-1 receptor (IL-1R) (TIR) domain, which mediates homotypic associations between TLRs and TIR-containing adaptors (Hayashi et al. 2001) . The structure of the TIR domain consists of a central five-stranded parallel β-sheet (βA-βE) surrounded by five helices (αA-αE) (Watters et al. 2007 ). Upon ligand-induced TLR dimerization or oligomerization, it is thought that a conformational change occurs in the cytoplasmic TIR domains that allows the recruitment of cytoplasmic adaptor proteins and subsequent engagement of downstream signaling molecules. Several proteins that interact with the TIR domains of TLRs were identified, including myeloid differentiation factor 88 (MyD88), MyD88 adapter-like (Mal)/TIR domain-containing adapter protein (TIRAP), TIR domain-containing adaptor-inducing interferon (IFN)-β (TRIF) and TRIF-related adaptor molecule (TRAM) ( Table 1) .
The first cytoplasmic adaptor found to be recruited to ligand-activated TLRs is myeloid differentiation factor 88 (MyD88), originally identified as a myeloid primary response gene rapidly induced by IL-6 in M1 myeloleukemic cells . MyD88 has a C-terminal TIR domain, which interacts with the TIR domain of all TLRs other than TLR3, while its N-terminus harbors a death domain (DD), initially implicated in TLR-induced cell death (Aliprantis et al. 1999) . TLR-induced apoptosis may play a role in resolution of inflammation by limiting the number of activated cells that produce pro-inflammatory mediators (Aliprantis et al. 1999 ), but can also compromise innate immunity . Nuclear factor-κB (NF-κB) and mitogen-activated protein kinases (MAPKs) are still weakly activated in the absence of MyD88, but tumor necrosis factor (TNF) is not produced in the absence of MyD88 (Gohda et al. 2004; O'Neill 2006) .
MyD88 adapter-like (Mal) (Fitzgerald et al. 2001) , also known as TIR domain-containing adapter protein (TI-RAP) (Horng et al. 2001) , is a bridging adaptor for MyD88, recruiting it to the TIR domains of TLR2 and TLR4. Mal contains a C-terminal phosphatidylinositol 4,5-bisphosphate (PIP2)-binding domain, which serves to localize it and its partners (i.e. MyD88) to membranes. Phosphorylation of Mal by Bruton's tyrosine kinase (Btk) is required for efficient signaling (Watters et al. 2007) .
TIR domain-containing adaptor-inducing IFN-β (TRIF) is an adaptor protein for TLR3 and TLR4. In addition to the TIR domain it has a TNF receptor (TNFR)-associated factor (TRAF)6-binding motif in its N-terminus, and a receptor-interacting protein (RIP) homotypic interaction motif (RHIM) in the C-terminus (Miggin and O'Neill 2006) . Overexpression of TRIF preferentially activates the IFN-β promoter (Akira 2003) . In macrophages of Mal/MyD88 double knockout mice, genes encoding IFN-inducible protein (IP)-10, immune-responsive gene (IRG)-1 and glucocorticoid-attenuated response gene (GARG)-16 (which are IFN-related genes) were induced normally in response to LPS, suggesting the existence of a MyD88-independent pathway. This pathway is dependent on TRIF (Miggin and O'Neill 2006) and TRAM (see further).
TRIF-related adaptor molecule (TRAM) acts as a bridge to couple TRIF to TLR4 and is required for TLR4-mediated MyD88-independent responses (Dunne and O'Neill 2005; Arancibia et al. 2007) . TRAM-deficient mice show defects in cytokine production and IFN-β induction only in response to TLR4 (Gohda et al. 2004) . TRAM is targeted to the cell membrane by N-terminal myristoylation (Watters et al. 2007) , which is essential for recruitment of TRIF to the membrane. Phosphorylation of TRAM on serine-16 by protein kinase C (PKC)ε is necessary for signaling and correlates with its removal from the membrane (Watters et al. 2007) .
The IL-1R-associated kinase (IRAK) family members IRAK1, IRAK2, IRAKM and IRAK4 contain an N-terminal death domain, a serine/threonine kinase domain and a TRAF-binding motif, which is absent from IRAK4 (Arancibia et al. 2007 ). IRAK1 and IRAK2 are essential for MAPK activation, but not for induction of NF-κB (Kawagoe et al. 2008) . The most profound phenotype of IRAK1-deficient mice is a complete impairment of IFN-α production (Uematsu et al. 2005) ; however, the exact role of IRAK1 in IFN induction is not clear. IRAK1 also has "PEST" sequences involved in proteolysis (Janssens and Beyaert 2003) , and is ubiquitinated and degraded by the proteasome after TLR or IL-1R stimulation (Yamin and Miller 1997; Li et al. 1999) . In contrast, the amount of IRAK2 is not altered in response to TLR stimulation (Kawagoe et al. 2008) .
In response to TLR stimulation, IRAK4 phosphorylates IRAK1 (Kollewe et al. 2004) . Phosphorylation of IRAK2 is also missing in IRAK4 -/-macrophages (Kawagoe et al. 2007) , suggesting that IRAK2 is also phosphorylated by IRAK4. These results indicate that IRAK4 acts upstream of both IRAK1 and IRAK2.
TNF receptor-associated factors (TRAFs) are really interesting new gene (RING) finger-containing proteins (with the exception of TRAF1) that share a conserved C-terminal "TRAF domain". Initially, TRAF6 was thought to be the sole member of this family to be involved in TLR signaling (Miggin and O'Neill 2006) . All MyD88-and TLR-dependent triggered pathways, which lead to activation of NF-κB and MAPKs, require TRAF6 (Gohda et al. 2004) . TRAF3 was only recently identified as a component of TLR signaling, being essential for the IFN response but not required for inflammatory cytokines and chemokines (Hacker et al. 2006; Miggin and O'Neill 2006) . TRAF1, by contrast, may be involved in inhibition of some (anti-viral) TLR activities (Miggin and O'Neill 2006) .
TRAF6 is a lysine 63 (K63)-specific E3 ubiquitin-protein ligase that functions together with ubiquitin-conjugating (Ubc) enzyme Ubc13 and ubiquitin E2 variant 1A (Uev1A) to catalyze the synthesis of K63-linked polyubiquitin chains on target proteins including TRAF6 itself (Kawagoe et al. 2008 ). Ubc13 in collaboration with its cofactor Uev1A binds the RING finger domains of TRAF proteins to promote activation of protein kinases involved in signaling by TNFRs and TLRs (Deng et al. 2000; Wang et al. 2001) . Unlike K48-linked polyubiquitination, which signals for proteasome-dependent protein degradation, K63-linked polyubiquitination is nondestructive and activates protein kinases (Fukushima et al. 2007 ). Knockout studies indicate that Ubc13, the only E2 dedicated to K63-linked ubiquitin conjugation is essential for TLR-dependent MAPK activation (Yamamoto et al. 2006) .
In general, the ubiquitination pathway causes covalent attachment of one or more ubiquitin molecules to proteins through the sequential action of three enzymes. First, the ubiquitin-activating enzyme (E1) activates ubiquitin by forming a thioester bond between ubiquitin and cysteine at the active site of E1. Next, the activated ubiquitin is transferred to a ubiquitin-conjugating enzyme (E2, or Ubc) to form a thioester linkage. Finally, ubiquitin ligases (E3) recruit the E2s to specific targets and promote the formation of an isopeptide bond between ubiquitin and lysine residues on the target protein (Ciechanover 2006) . There is only one E1, but many E2s, and even more E3s (Ciechanover 2006) .
Signaling elicited by activated TLRs
After binding of MyD88 to ligand-activated TLRs, MyD88 recruits members of the IRAK family; particularly IRAK1 and IRAK4, through homotypic interactions between their death domains. IRAK4 then phosphorylates IRAK1 (and possibly IRAK2), which subsequently associates with TRAF6 (Miggin and O'Neill 2006) . TRAF6 is then activated through self-ubiquitination with the assistance of Ubc13 and Uev1A (Watters et al. 2007; Kawagoe et al. 2008) . TRAF6 and IRAK1 then dissociate from the receptor and interact with a membrane-bound pre-associated complex of transforming growth factor (TGF)-β-activated kinase (TAK) 1 -a member of the MAP3K family, and its binding proteins TAB1 and TAB2. The exact order of these events has not been determined; however, ubiquitination of TRAF6 is required for its interaction with TAB2, which binds to K63-linked polyubiquitin chains through its zinc finger domain (Evans 2005 ). Subsequently, phosphorylation of TAK1 and TAB2 induce IRAK1 degradation, leading to dissociation of the TRAF6:TAK1:TAB1:TAB2 complex from the membrane to the cytosol. TRAF6 then activates TAK1 and modifies NF-κB essential modulator (NEMO)/ inhibitor κB kinase (IKK)γ -the regulatory subunit of the IKK complex, via K63-linked ubiquitination (Evans 2005; Arancibia et al. 2007 ). K63-specific ubiquitination of RIP1 maybe also important, causing RIP1 to bind TAB proteins (Evans 2005) . Once activated, TAK1 phosphorylates IKKβ. IKK activation during IL-1R/TLR signaling is thought to occur in the cytosol, which differs from IKKβ activation during TNFR1 signaling, where TRAF2 and IKK are recruited to the receptor complex through binding to RIP (Evans 2005) . The activated IKK complex induces phosphorylation and subsequent degradation of IκB, thereby leading to nuclear translocation of NF-κB and expression of pro-inflammatory cytokines. TAK1 also phosphorylates MAPK kinase (MKK)3, 4, 6 and 7, which in turn activate p38 and c-Jun N-terminal kinase (JNK) (Wang et al. 2001 ). The exact order of these events is poorly understood and the results described above only provide a rough outline of the mechanisms involved in IKK and MAPK activation.
It was also shown that TRIF bound to TLR3 recruits TRAF6 directly through a TRAF6-binding motif in its Nterminus . TRIF also associates with RIP1 through its C-terminal RHIM domain; and in the absence of RIP1, TLR3-mediated NF-κB activation is abolished, suggesting that RIP1 and TRAF6 mediate TRIFinduced NF-κB activation (Meylan et al. 2004) . TRIF can also activate NF-κB through an alternative pathway. Pretreatment of MyD88-deficient cells with soluble TNFR1, or depletion of IFN regulatory factor (IRF)-3, blocked LPS-stimulated activation of NF-κB indicating the involvement of TNF and IRF-3 . This might also explain why LPS-stimulated TRAF6-deficient macrophages are still capable of delayed NF-κB activation LPS does not activate NF-κB in RIP1/MyD88 double deficient cells indicating the requirement of RIP1 for TRIF-dependent TLR4-induced NF-κB pathway (CussonHermance et al. 2005) . While MyD88 and Mal mediate the early phase of NF-κB activation, TRIF and TRAM mediate the late phase of NF-κB activation and the second pathway that depends on production of IFN-β (via the transcription factor IRF-3) (Dunne and O'Neill 2005; Sasai et al. 2005) .
The N-terminus of TRIF also contains binding sites for the non-canonical IKK family members, IKKi/IKKε and TRAF family member-associated NF-κB activator (TANK)-binding kinase 1 (TBK1), which were discovered based on sequence homology and the potential to stimulate NF-κB signaling. It was believed that they associate with TANK (Dunne and O'Neill 2005) , however, it was revealed that it is the TANK homolog, NAP1 (NF-κB-activating kinase (NAK)-associated protein 1) that forms a functional complex with TBK1 and IKKi rather than TANK itself (Sasai et al. 2005) . As mentioned, TRAF6 and RIP-1 are thought to mediate TRIF-induced NF-κB activation; whereas IKKi and TBK1 (with NAP1) are required for TRIF-induced IRF-3 activation (Dunne and O'Neill 2005) , which also depends on TRAF3 (Hacker et al. 2006 ). The primary targets of the IKK-related kinases are IRF-3 and IRF-7, transcriptional mediators of anti-viral activities (Hiscott 2007) .
Detection of virus infection and induction of appropriate anti-viral responses by producing type I IFNs (IFN-α and IFN-β) and IFN-related proteins, such as IP-10, a member of the CXC chemokine family, monocyte chemotactic protein (MCP)-1, GARG-16, IRG-1 and regulated and normal T cell expressed and secreted (RANTES)/CC chemokine ligand (CCL)5 (Gohda et al. 2004; Miggin and O'Neill 2006) , is an important effector function of some TLRs. TRIF and/or TRAM activate the signaling pathway leading to production of IFN through activation of transcription factor IRF-3 in a manner dependent on the IKK-related kinases IKKi and TBK1 (Dunne and O'Neill 2005) . The model of IRF-3 activation proposes that phosphorylation induces a conformational change that allows IRF-3 homo-or heterodimerization, nuclear localization and association with the coactivator CBP/p300. Phosphorylation-dependent association with CBP/p300 retains IRF-3 in the nucleus and induces transcription of IFN-β, as well as other IFN-response genes. Recently, IRF-1 has been identified as an additional transcription factor activated by MyD88, inducing IFN-β, inducible NO synthase and IL-12p35 (Negishi et al. 2006) .
IFN-α production requires the transcription factor IRF-7, which has been shown to associate with MyD88, IRAK1, IRAK4 and TRAF6 (Kawai et al. 2004; O'Neill 2006; Watters et al. 2007 ). Ubc13 is also required for the activation of IRF-7 (Uematsu et al. 2005 ), but the K63-specific E3 ligase that is involved or its target are unknown (it could be TRAF3, see later). TBK1 and IKKi have been shown to phosphorylate and activate IRF-7 as well (Fitzgerald et al. 2003) . IRF-5, like IRF-7, complexes with both MyD88 and TRAF6 . In IRF-5-deficient cells the induction of inflammatory cytokines is severely impaired, whereas IFN-α production is not affected (Watters et al. 2007) .
Importantly, viral infection is also detected through TLR-independent mechanisms (Hiscott 2007) . Early viral replicative intermediates are detected by two recently characterized cytosolic viral RNA receptors -RIG-I (retinoic acid-inducible gene-I) (Yoneyama et al. 2004 ) and Mda5 (melanoma differentiation-associated gene 5) (Andrejeva et al. 2004 ). Signaling by RIG-I and Mda5 to IRF-3 is also TRAF3-dependent (Pietras et al. 2006) .
Evidences are beginning to emerge about the unique role of TRAF3 in TLR signaling. TRAF3 has been shown earlier to be essential for the induction of type I interferons and the anti-inflammatory cytokine IL-10 ( Hacker et al. 2006) , which in the case of TLR3 and TLR4 are dependent on IRF3 activation (Doyle et al. 2002) . The IFN response can repress tumor growth and (especially IFN-β) has protective function in osteoporosis, whereas TNF and other inflammatory cytokines can promote tumor growth and bone resorption (Takayanagi et al. 2002 (Takayanagi et al. , 2005 Luo et al. 2004; Lin and Karin 2007) . New data indicate that the final outcome of TLR signaling -the selective production of type I IFNs versus proinflammatory cytokines, is controlled by differential ubiquitination of TRAF3 (Tseng et al. 2010) . Whereas the TRIF-dependent response is critical for IFN and IFN-related gene induction, the induction of proinflammatory cytokines is mediated mainly by MyD88-dependent signaling (Yamamoto et al. 2002; Hoebe et al. 2003) . TRIF-mediated signaling triggered K63-linked self-ubiquitination of TRAF3, and was shown to be essential for activation of IRF3 and the IFN response. By contrast, MyD88-dependent signaling led to degradative ubiquitination of TRAF3, resulting in induction of the inflammatory response through activation of MAPK. Activation of the K48-specific ubiquitin ligases cIAP1/2 (present only within the MyD88-assembled, but not within the TRIF-assembled signaling complex, which is sorted into endosomes) by its relative TRAF6 was required for ubiquitination of TRAF3.
In TLR signaling, the K63-specific polyubiquitination is mediated mainly by the ubiquitin-conjugating enzyme Ubc13. Whereas both TRAF2 and TRAF6 are K63-specific E3 ubiquitin ligases which require Ubc13, TRAF3 ubiquitination is not totally dependent on Ubc13 (M. Karin, personal communication). Interestingly, it has been demonstrated that Ubc13 deficiency preferentially affects activation of MAP kinases and production of pro-inflammatory cytokines, providing additional level of specificity (Yamamoto et al. 2006) .
It has been published recently that activation of signaling cascades at CD40 is a two-stage process, and only occurs upon release of the receptor-tethered signaling complex; mediated by the cellular inhibitor of apoptosis (c-IAP)-dependent degradation of TRAF3, both components of the same signaling complex (Matsuzawa et al. 2008) . Similarly, c-IAP-mediated degradation of TRAF3 is required in MyD88-dependent TLR signaling to MAPKs, and proceeds via the same two stage mechanism shown for CD40 (Tseng et al. 2010 ). TRAF6 activation, in addition to K63-linked self-ubiquitination, induces the Ubc13-dependent K63-linked ubiquitination of c-IAP1/2; resulting in c-IAP1/2 activation (as TRAF3 K48-specific E3 ligases), and degradation of TRAF3 (c-IAP is an anti-apoptotic protein with a K48-specific E3 ubiquitin-protein ligase activity, Figure 1 . A simplified diagram of signal transduction pathways elicited by activated TLRs. IRFs can form homo-as well as heterodimers (only heterodimers are shown for the sake of simplicity). Circled P indicates phosphorylation, circled Ub denotes ubiquitination (red, degradative K48-linked; blue, K63-linked polyubiquitination). cIAP, cellular inhibitor of apoptosis; IFN, interferon; IκB, inhibitor κB; IKK, IκB kinase; IL, interleukin; IRAK, IL-1 receptor (IL-1R)-associated kinase; IRF, IFN regulatory factor; JNK, c-Jun N-terminal kinase; Mal, MyD88 adapter-like; Mda5, melanoma differentiation-associated gene 5; MEKK, mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) kinase kinase; MKK, MAPK kinase; MyD88, myeloid differentiation factor 88; NAP1, NF-κB-activating kinase (NAK)-associated protein 1; RIG-I, retinoic acid-inducible gene-I; RIP1, receptor-interacting protein 1; TAB, TAK1-binding protein; TAK1, transforming growth factor (TGF)-β-activated kinase 1; TBK1, TRAF family member-associated NF-κB activator (TANK)-binding kinase 1; TLR, toll-like receptor; TRAF, tumor necrosis factor (TNF) receptor (TNFR)-associated factor; TRAM, TRIF-related adaptor molecule; TRIF, toll/interleukin-1 receptor (TIR) domain-containing adaptor-inducing IFN-β; Ubc13, ubiquitin-conjugating enzyme 13. whose expression is induced by NF-κB). Once TRAF3 is degraded, the entire MyD88-associated signaling complex translocates to the cytosol, where TAK1 is activated to allow MAPK signaling.
Negative regulation of TLR signaling
Inhibitory soluble forms of TLR2 and TLR4 have been described, produced by post-translational modification or alternative splicing, respectively (Arancibia et al. 2007) .
A splice variant of MyD88, termed MyD88s, inhibits NF-κB by preventing the association IRAK1 with IRAK4, and the subsequent activation of IRAK1.
IRAKM, a kinase inactive IRAK family member, prevents the dissociation of IRAK1 from MyD88, and the subsequent association of IRAK1 with the downstream adaptor TRAF6 (Kobayashi et al. 2002) .
Another TRAF family member, TRAF1, has been shown to interact with the TIR domain of TRIF, resulting in its inhibition (Miggin and O'Neill 2006) .
Sterile α-and armadillo-motif containing protein (SARM), the fifth TIR domain-containing adaptor associates with TRIF and blocks TRIF-induced NF-κB activation (Carty et al. 2006; Watters et al. 2007 ). The mechanisms of SARM action involved its two tandem sterile α-motif (SAM) domains as well.
Mal is subject to negative regulation mediated by suppressor of cytokine signaling (SOCS)1. It was shown that SOCS1 mediates K48-linked polyubiquitination of Mal on two N-terminal lysines, thereby mediating Mal degradation via the 26S proteasome (Mansell et al. 2006) . A prerequisite for Mal degradation is tyrosine phosphorylation by Btk, as this may allow SOCS1 to associate with Mal through its SH2 domain. As already mentioned, phosphorylation of Mal by Btk potentiate signaling; thus phosphorylation by Btk allows a transient activation of downstream signaling pathways before Mal is targeted to degradation (Watters et al. 2007 ).
Triad3A is a novel RING-type E3 ubiquitin ligase which promotes the degradation of TLR3, TLR4, TLR5 and TLR9, but not TLR2 (Chuang and Ulevitch 2004) .
The two deubiquitinating enzymes, A20 and CYLD, are induced by NF-κB and form an important negative-feedback loop in pro-inflammatory signaling. They function by removing K63-linked polyubiquitin chains from RIP1, TRAF and NEMO proteins (Evans 2005) . A20, induced at a transcriptional level by NF-κB, terminates TLR signaling by removing ubiquitin moieties from TRAF6 (Miggin and O'Neill 2006) . It also inhibits TNF and IL-1 signaling (Opipari et al. 1992; Jaattela et al. 1996) . The N-terminal portion of A20 binds TRAF molecules, and the C-terminal region, containing seven Zn fingers, interacts with NEMO and IKKα (Evans 2005) . CYLD, identified as a tumor suppressor gene that is mutated in familiar cylindromatosis (a benign skin tumor) (Bignell et al. 2000) , removes K63-linked polyubiquitin chains from TRAF2 and NEMO, and inhibits their activities (Brummelkamp et al. 2003; Kovalenko et al. 2003; Trompouki et al. 2003) .
The TIR domain containing protein of vaccinia virus, A46R, sequesters TRIF via homophilic TIR domain interactions and inhibits TRIF-induced IRF-3 activation; and also targets MyD88 and TRAM (Watters et al. 2007) .
A serine protease of hepatitis C virus is known to cause proteolysis of TRIF (Watters et al. 2007 ).
TGF-β partly exerts its anti-inflammatory effects by causing direct ubiquitination of MyD88, thereby augmenting its degradation by the proteasome (Naiki et al. 2005; Watters et al. 2007) .
Glucocorticoids also inhibit actions of some TLRs, as discussed below.
Specificity at the promoter level
It was found that TLR3 and TLR4 differently regulate the IFN response. When TLR3 is activated, IRF-3 homodimers are tethered on the regulatory regions of target genes, which contain IFN-sensitive response elements (ISRE), such as IFN-β. However, when TLR4 is activated, a complex of IRF-3 and the NF-κB subunit p65 is formed and so NF-κB plays a key role in the function of IRF-3 during TLR4 signaling (Wietek et al. 2003) . Glucocorticoids were found to repress the induction of ISRE-containing genes, but only when activated by TLR4 as opposed to TLR3, because they specifically target and disrupt the p65/IRF complex .
Another example of promoter-specificity is the finding that two IFN-related genes, MCP-1 and IP-10, are differently regulated by NF-κB. Only one nucleotide in the promoter-sequence determined the specific regulation profile (as a consequence of specificity of dimer and coactivator recruitments) (Leung et al. 2004) . It was demonstrated that while the transcription of MCP-1 and IP-10 could be induced by LPS in both wild type and p50/p52-deficient cells, only MCP-1 responded to TNF-stimulation in p50/p52-deficient cells, where the only detectable NF-κB dimer on the promoter was the p65 homodimer (Leung et al. 2004) . The unresponsiveness of the IP-10 gene to p65 homodimers in the TNF-treated cells is a consequence of the lack of a cofactor (IRF-3 functions as a cofactor here) that LPS can induce. Chromatin immunoprecipitation assays demonstrated that IRF-3 was tethered to the IP-10 promoter, but not the MCP-1 promoter, in an LPS-dependent manner . Under TNF stimulation, however, IRF-3 is not activated. Similar promoter-selective effects of p38 and JNK were observed using glucocorticoid-responsive regulatory sequences (Szatmary and Kebis 2012) indicating that the interplay between glucocorticoids and pro-inflammatory stimuli is mutually selective. Figure 1 depicts a simplified diagram of signal transduction pathways elicited by activated TLRs. Defective TLR-mediated signaling pathways are involved in the pathogenesis of many autoimmune (e.g., TLR2/4 have been shown to be involved in rheumatoid arthritis, and TLR7/8/9 in the pathogenesis of systemic lupus erythematosus, respectively) and other disorders, therefore their elucidation is a critical prerequisite for the development of new, effective therapies of these diseases.
Concluding remark

